Skip to content
Clolar, Evoltra(clofarabine)
Clolar, Evoltra (clofarabine) is a small molecule pharmaceutical. Clofarabine was first approved as Clolar on 2004-12-28. It is used to treat lymphoid leukemia in the USA. It has been approved in Europe to treat precursor cell lymphoblastic leukemia-lymphoma. The pharmaceutical is active against ribonucleoside-diphosphate reductase subunit M2. In addition, it is known to target ribonucleoside-diphosphate reductase large subunit and high affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A.
Download report
Favorite
Drugs Approved for Childhood Cancers
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
Clolar (generic drugs available since 2017-05-09)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Clofarabine
Tradename
Company
Number
Date
Products
CLOLARSanofiN-021673 RX2004-12-28
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
clofarabineANDA2023-02-15
clolarNew Drug Application2020-10-15
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
lymphoid leukemia—D007945C91
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01B: Antimetabolites
— L01BB: Purine analogs, antimetabolites antineoplastic
— L01BB06: Clofarabine
HCPCS
Code
Description
J9027
Injection, clofarabine, 1 mg
Clinical
Clinical Trials
163 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloid leukemia acuteD015470C92.021464—163
Myelodysplastic syndromesD009190D4620312——45
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.016283——41
LeukemiaD007938C9522263——39
Myeloid leukemiaD007951C92111——3
Megakaryoblastic leukemia acuteD007947C94.21—1——2
Monocytic leukemia acuteD0079481—1——2
Myelomonocytic leukemia acuteD015479C92.51—1——2
Erythroblastic leukemia acuteD004915EFO_1001257C94.01—1——2
Stem cell transplantationD033581—11——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-hodgkin lymphomaD008228C85.9712———15
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_000034028———10
Myelomonocytic leukemia chronicD015477C93.147———10
Hodgkin diseaseD006689C8157———9
NeoplasmsD009369C8062——18
B-cell chronic lymphocytic leukemiaD015451C91.155———8
LymphomaD008223C85.955———7
Multiple myelomaD009101C90.025———6
Hematologic neoplasmsD01933741——15
Burkitt lymphomaD002051C83.724———4
Show 37 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloproliferative disordersD009196D47.12————2
Lymphoproliferative disordersD008232Orphanet_2442D47.91————1
Primary myelofibrosisD055728D47.41————1
NeutropeniaD009503D701————1
Bone marrow diseasesD0018551————1
Bone marrow transplantationD0160261————1
Rheumatoid arthritisD001172EFO_0000685M06.91————1
Crohn diseaseD003424EFO_0000384K501————1
Autoimmune diseasesD001327EFO_0000540M30-M361————1
Systemic lupus erythematosusD008180EFO_0002690M321————1
Show 4 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Peroxisomal disordersD018901EFO_0010956E71.5————11
Lysosomal storage diseasesD016464————11
Sickle cell anemiaD000755EFO_0000697D57————11
ThalassemiaD013789EFO_1001996D56————11
Fanconi anemiaD005199Orphanet_84D61.09————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCLOFARABINE
INNclofarabine
Description
Clofarabine is a purine nucleoside analogue consisting of a 6-amino-2-chloropurin-9-yl group attached to the 1beta position of 2'-deoxy-2'-fluoro-D-arabinofuranose. It is metabolized intracellularly to the active 5'-triphosphate metabolite, which inhibits DNA synthesisis and so stops the growth of cancer cells. Clofarabine is used as an antimetabolite antineoplastic agent in the treatment of relapsed or refractory acute lymphoblastic leukaemia. It has a role as an antineoplastic agent and an antimetabolite. It is an organofluorine compound and a member of adenosines.
Classification
Small molecule
Drug classantineoplastics (arabinofuranosyl derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Identifiers
PDB7CWA
CAS-ID123318-82-1
RxCUI44151
ChEMBL IDCHEMBL1750
ChEBI ID681569
PubChem CID119182
DrugBankDB00631
UNII ID762RDY0Y2H (ChemIDplus, GSRS)
Target
Agency Approved
RRM2
RRM2
Organism
Homo sapiens
Gene name
RRM2
Gene synonyms
RR2
NCBI Gene ID
6241
Protein name
ribonucleoside-diphosphate reductase subunit M2
Protein synonyms
ribonucleotide reductase M2 polypeptide, Ribonucleotide reductase small chain, Ribonucleotide reductase small subunit, uncharacterized protein C2orf48
Uniprot ID
Q5WRU7
Mouse ortholog
Rrm2 (20135)
ribonucleoside-diphosphate reductase subunit M2 (Q542E2)
Alternate
RRM1
RRM1
PDE8A
PDE8A
Organism
Homo sapiens
Gene name
RRM1
Gene synonyms
RR1
NCBI Gene ID
6240
Protein name
ribonucleoside-diphosphate reductase large subunit
Protein synonyms
Ribonucleoside-diphosphate reductase subunit M1, Ribonucleotide reductase large subunit, ribonucleotide reductase M1 polypeptide, ribonucleotide reductase, R1 subunit
Uniprot ID
Q9UNN2
Mouse ortholog
Rrm1 (20133)
ribonucleoside-diphosphate reductase large subunit (Q91YM8)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,485 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
5,006 adverse events reported
View more details